Latest news with #NostrumLaboratories
Miami Herald
16-07-2025
- Business
- Miami Herald
Drug recalled by a Miami man's dying company that faced Medicaid fraud charges
All bottles of an ulcer medication have been recalled by the remains of a Kansas City drug company that filed Chapter 11 bankruptcy after paying millions to settle Medicaid fraud charges. Nostrum Laboratories, which recalled 1 gram Sulcralfate Tablets on Friday, is in Kansas City at 1800 N. Topping Ave. Online county property records say Nostrom's founder and CEO, Nirmal Mulye, lives in a $5 million, 4,600-square-foot condo on Miami's Biscayne Boulevard. Mulye's LinkedIn profile says he's got other jobs with Nostrum's 'family of pharmaceutical and energy companies.' No operational employees have jobs at Nostrum Laboratories — they all were fired after the company filed for bankruptcy on Sept. 30, 2024. No employees means no one is in quality control. So, Nostrum's recall notice said, the company can't 'assure that this product meets the identity, strength, quality, and purity characteristics that it is purported or represented to possess. While specific risks to patients from use of an adulterated product cannot always be identified or assessed, it is also not possible to rule out patient risks resulting from the use of such a product.' In short, Nostrum can't guarantee that the Sulcralfate will work as it should and isn't contaminated. The National Library of Medicine says Sulcrafate is for 'short-term treatment (up to 8 weeks) of an active duodenal ulcer' or 'maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.' This involves 1 gram Sulcralfate Tablets in 100-count or 500-count bottles, all lots, made by Nostrum after June 2023. Nostrum's notice tells wholesalers and distributors to destroy the tablets and that 'Nostrum Labs is not accepting any returns of this product.' Customers should contact the prescribing medical professional or their pharmacist for different treatment options. If Sulcrafate users suffer a medical problem, notify a medical professional then notify the FDA's MedWatch Adverse Event reporting program. Direct questions about the recall to Nostrum at recallcoordinator@ Drug prices and Medicaid Mulye jumped into the national drug cost discussion for a time in 2018 after being quoted in a Financial Times article justifying a 400% increase in a urinary tract infection drug. Clarifying his statement to CNBC, Mulye pointed the finger at the FDA for overregulation and inefficiencies that created the mise en scène for actions of Martin Shkreli, the drug executive who jacked up the price of one drug 5000% in 2015. READ MORE: CEO who hiked drug price 400% fires back at U.S. Senator, says he got death threats In 2023, the U.S. Justice Department charged Nostrum and Mulye with intentionally underpaying Medicaid rebates concerning the drug nitrofurantonin or Nitro OS. As explained by the Justice Department, drugmakers 'pay quarterly rebates to state Medicaid programs in exchange for Medicaid's coverage of the manufacturers' drugs. The (Medicaid Drug Rebate Program) requires manufacturers to pay inflation-based rebates for drugs,' to protect the Medicaid programs from major jumps in drug price. The rebates are determined by the drug's current price and the price when that dosage form and strength was first marketed. Nostrum took Nitro OS off the market in January 2018 to comply with new FDA guidelines, then relaunched it in August 2018. Nostrum admitted it did so without changes in dosage form and strength to Nitro OS. Same drug, new price — from $474.75 to $2,392.32 per bottle. That meant Nostrum should pay larger Medicaid rebates, but Nostrum admits it didn't from the last quarter of 2018 through the first quarter of 2020. The minimum Nostrum would pay in the settlement, Justice said, was $3,825,000, and the most would be $50 million. 'Nostrum Laboratories reduced the amount that it paid to the Medicaid program by improperly calculating the rebates it owed, even after hiking the cost of one of their drugs by over 400%,' said FBI Boston Field Office Special Agent in Charge Jodi Cohen.
Business Standard
30-04-2025
- Business
- Business Standard
Strides Pharma's US arm acquires four drugs to bolster portfolio
Strides Pharma Science said that its step-down wholly owned subsidiary in the US, Stride Pharma Inc, has acquired four approved ANDAs for the US Market from Nostrum Laboratories, Inc., USA. The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy. Two (out of the four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products. The cumulative market size for the acquired portfolio is around $57 million as per IQVIA data of 2025. Total consideration for acquisition of the said ANDAs is $ 2.075 million (Rs 17.6 crore). Strides Pharma Science is global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures wide range of niche and technically complex pharmaceutical products The companys consolidated net profit jumped 77.1% to Rs 87.95 crore on 14.7% increase in net sales to Rs 1153.67 crore in Q3 FY25 over Q3 FY24. The counter declined 1.61% to end at Rs 652.55 on Tuesday, 29 April 2025.
